You have full text access to this OnlineOpen article

Porcine left atrial and sinoatrial 5-HT4 receptor-induced responses: fading of the response and influence of development

  1. Joris H De Maeyer1,2,*,
  2. Roel Straetemans2,
  3. Jan A J Schuurkes2,
  4. Romain A Lefebvre1

Article first published online: 29 JAN 2009

DOI: 10.1038/sj.bjp.0706497

Issue

British Journal of Pharmacology

British Journal of Pharmacology

Volume 147, Issue 2, pages 140–157, January 2006

Additional Information

How to Cite

De Maeyer, J. H., Straetemans, R., Schuurkes, J. A. J. and Lefebvre, R. A. (2006), Porcine left atrial and sinoatrial 5-HT4 receptor-induced responses: fading of the response and influence of development. British Journal of Pharmacology, 147: 140–157. doi: 10.1038/sj.bjp.0706497

Author Information

  1. 1

    Heymans Institute of Pharmacology, Ghent University, Ghent, Belgium

  2. 2

    Johnson & Johnson Pharmaceutical Research & Development, A Division of Janssen Pharmaceutica N.V., Beerse, Belgium

*Heymans Institute of Pharmacology, Ghent University, De Pintelaan 185, 9000 Ghent, Belgium; E-mail: jdmaeyer@prdbe.jnj.com

Publication History

  1. Issue published online: 29 JAN 2009
  2. Article first published online: 29 JAN 2009
  3. (Received June 21, 2005, Revised August 15, 2005, Accepted August 16, 2005)

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (323K)

References

  • ANSANAY, H., SEBBEN, M., BOCKAERT, J. & DUMUIS, A. (1992). Characterization of homologous 5-hydroxytryptamine4 receptor desensitization in colliculi neurons. Mol. Pharmacol., 42, 808–816.
  • BACH, T., SYVERSVEEN, T., KVINGEDAL, A.M., KROBERT, K.A., BRATTELID, T., KAUMANN, A.J. & LEVY, F.O. (2001). 5HT4(a) and 5-HT4(b) receptors have nearly identical pharmacology and are both expressed in human atrium and ventricle. Naunyn-Schmiedeberg's Arch. Pharmacol., 363, 146–160.
  • BAILLIE, G.S. & HOUSLAY, M.D. (2005). Arrestin times for compartmentalised cAMP signalling and phosphodiesterase-4 enzymes. Curr. Opin. Cell. Biol., 17, 129–134.
  • BEATTIE, D.T., SMITH, J.A., MARQUESS, D., VICKERY, R.G., ARMSTRONG, S.R., PULIDO-RIOS, T., MCCULLOUGH, J.L., SANDLUND, C., RICHARDSON, C., MAI, N. & HUMPHREY, P.P. (2004). The 5-HT4 receptor agonist, tegaserod, is a potent 5-HT2B receptor antagonist in vitro and in vivo. Br. J. Pharmacol., 143, 549–560.
    Direct Link:
  • BERTHOUZE, M., AYOUB, M., RUSSO, O., RIVAIL, L., SICSIC, S., FISCHMEISTER, R., BERQUE-BESTEL, I., JOCKERS, R. & LEZOUALC'H, F. (2005). Constitutive dimerization of human serotonin 5-HT4 receptors in living cells. FEBS Lett., 579, 2973–2980.
  • BLONDEL, O., GASTINEAU, M., DAHMOUNE, Y., LANGLOIS, M. & FISCHMEISTER, R. (1998). Cloning, expression, and pharmacology of four human 5-hydroxytryptamine4 receptor isoforms produced by alternative splicing in the carboxyl terminus. J. Neurochem., 70, 2252–2261.
    Direct Link:
  • BLONDEL, O., VANDECASTEELE, G., GASTINEAU, M., LECLERC, S., DAHMOUNE, Y., LANGLOIS, M. & FISCHMEISTER, R. (1997). Molecular and functional characterization of a 5-HT4 receptor cloned from human atrium. FEBS Lett., 412, 465–474.
  • BOCKAERT, J., CLAEYSEN, S., COMPAN, V. & DUMUIS, A. (2004). 5-HT4 receptors. Curr. Drug Targets CNS Neurol. Disord., 3, 39–51.
  • BRATTELID, T., KVINGEDAL, A.M., KROBERT, K.A., ANDRESSEN, K.W., BACH, T., HYSTAD, M.E., KAUMANN, A.J. & LEVY, F.O. (2004a). Cloning, pharmacological characterisation and tissue distribution of a novel 5-HT4 receptor splice variant, 5-HT4(i). Naunyn-Schmiedeberg's Arch. Pharmacol., 369, 616–628.
  • BRATTELID, T., QVIGSTAD, E., LYNHAM, J.A., MOLENAAR, P., AASS, H., GEIRAN, O., SKOMEDAL, T., OSNES, J.B., LEVY, F.O. & KAUMANN, A.J. (2004b). Functional serotonin 5-HT4 receptors in porcine and human ventricular myocardium with increased 5-HT4 mRNA in heart failure. Naunyn-Schmiedeberg's Arch. Pharmacol., 370, 157–166.
  • BRIEJER, M.R., BOSMANS, J.P., VAN DAELE, P., JURZAK, M., HEYLEN, L., LEYSEN, J.E., PRINS, N.H. & SCHUURKES, J.A. (2001). The in vitro pharmacological profile of prucalopride, a novel enterokinetic compound. Eur. J. Pharmacol., 423, 71–83.
  • CARLISLE MICHEL, J.J., DODGE, K.L., WONG, W., MAYER, N.C., LANGEBERG, L.K. & SCOTT, J.D. (2004). PKA-phosphorylation of PDE4D3 facilitates recruitment of the mAKAP signalling complex. Biochem J., 381, 587–592.
  • CASTRO, L., MIALET-PEREZ, J., GUILLEMEAU, A., STILLITANO, F., ZOLK, O., ESCHENHAGEN, T., LEZOUALCh, F., BOCHET, P. & FISCHMEISTER, R. (2005). Differential functional effects of two 5-HT4 receptor isoforms in adult cardiomyocytes. J. Mol. Cell. Cardiol., 39, 335–344.
  • CLAEYSEN, S., SEBBEN, M., BECAMEL, C., BOCKAERT, J. & DUMUIS, A. (1999). Novel brain-specific 5-HT4 receptor splice variants show marked constitutive activity: role of the C-terminal intracellular domain. Mol. Pharmacol., 55, 910–920.
  • DODGE, K.L., KHOUANGSATHIENE, S., KAPILOFF, M.S., MOUTON, R., HILL, E.V., HOUSLAY, M.D., LANGEBERG, L.K. & SCOTT, J.D. (2001). mAKAP assembles a protein kinase A/PDE4 phosphodiesterase cAMP signaling module. EMBO J., 20, 1921–1930.
  • EGLEN, R.M., WONG, E.H., DUMUIS, A. & BOCKAERT, J. (1995). Central 5-HT4 receptors. Trends Pharmacol. Sci., 16, 391–398.
  • FERGUSON, S.S. (2001). Evolving concepts in G protein-coupled receptor endocytosis: the role in receptor desensitization and signaling. Pharmacol. Rev., 53, 1–24.
  • GALE, J.D., GROSSMAN, C.J., WHITEHEAD, J.W., OXFORD, A.W., BUNCE, K.T. & HUMPHREY, P.P. (1994). GR113808: a novel, selective antagonist with high affinity at the 5-HT4 receptor. Br. J. Pharmacol., 111, 332–338.
  • GARVEY, J.L., KRANIAS, E.G. & SOLARO, R.J. (1988). Phosphorylation of C-protein, troponin I and phospholamban in isolated rabbit hearts. Biochem. J., 249, 709–714.
  • GERALD, C., ADHAM, N., KAO, H.T., OLSEN, M.A., LAZ, T.M., SCHECHTER, L.E., BARD, J.A., VAYSSE, P.J., HARTIG, P.R. & BRANCHEK, T.A. (1995). The 5-HT4 receptor: molecular cloning and pharmacological characterization of two splice variants. EMBO J., 14, 2806–2815.
  • GRAMMER, J.B., ZENG, X., BOSCH, R.F. & KUHLKAMP, V. (2001). Atrial L-type Ca2+-channel, β-adrenorecptor, and 5-hydroxytryptamine type 4 receptor mRNAs in human atrial fibrillation. Basic Res. Cardiol., 96, 82–90.
  • GUO, Z.G., LEVI, R., AARONSON, L.M. & GAY, W.A. (1983). The isolated human pectinate muscle: a reliable preparation of human cardiac tissue. J. Pharmacol Methods, 9, 127–135.
  • HANOUZ, J.L., PERSEHAYE, E., ZHU, L., LAMMENS, S., LEPAGE, O., MASSETTI, M., BABATASI, G., KHAYAT, A., BRICARD, H. & GERARD, J.L. (2004). The inotropic and lusitropic effects of ketamine in isolated human atrial myocardium: the effect of adrenoceptor blockade. Anesth. Analg., 99, 1689–1695.
  • HEUBACH, J.F., RAVENS, U. & KAUMANN, A.J. (2004). Epinephrine activates both Gs and Gi pathways, but norepinephrine activates only the Gs pathway through human β2-adrenoceptors overexpressed in mouse heart. Mol. Pharmacol., 65, 1313–1322.
  • JAHNEL, U., RUPP, J., ERTL, R. & NAWRATH, H. (1992). Positive inotropic response to 5-HT in human atrial but not in ventricular heart muscle. Naunyn-Schmiedebergs Arch. Pharmacol., 346, 482–485.
  • JOUBERT, L., HANSON, B., BARTHET, G., SEBBEN, M., CLAEYSEN, S., HONG, W., MARIN, P., DUMUIS, A. & BOCKAERT, J. (2004). New sorting nexin (SNX27) and NHERF specifically interact with the 5-HT4(a) receptor splice variant: roles in receptor targeting. J. Cell Sci., 117, 5367–5379.
  • JUREVICIUS, J. & FISCHMEISTER, R. (1996). cAMP compartmentation is responsible for a local activation of cardiac Ca2+ channels by β-adrenergic agonists. Proc. Natl. Acad. Sci. U.S.A., 93, 295–299.
  • KAUMANN, A., BARTEL, S., MOLENAAR, P., SANDERS, L., BURRELL, K., VETTER, D., HEMPEL, P., KARCZEWSKI, P. & KRAUSE, E.G. (1999). Activation of β2-adrenergic receptors hastens relaxation and mediates phosphorylation of phospholamban, troponin I, and C-protein in ventricular myocardium from patients with terminal heart failure. Circulation., 99, 65–72.
  • KAUMANN, A.J. (1990). Piglet sinoatrial 5-HT receptors resemble human atrial 5-HT4-like receptors. Naunyn-Schmiedeberg's Arch. Pharmacol., 342, 619–622.
  • KAUMANN, A.J. (1994). Do human atrial 5-HT4 receptors mediate arrhythmias Trends Pharmacol. Sci., 15, 451–455.
  • KAUMANN, A.J., LYNHAM, J.A. & BROWN, A.M. (1995). Labelling with [125I]-SB 207710 of a small 5-HT4 receptor population in piglet right atrium: functional relevance. Br. J. Pharmacol., 115, 933–936.
  • KAUMANN, A.J., LYNHAM, J.A. & BROWN, A.M. (1996). Comparison of the densities of 5-HT4 receptors, β1- and β2-adrenoceptors in human atrium: functional implications. Naunyn-Schmiedebergs Arch. Pharmacol., 353, 592–595.
  • KAUMANN, A.J., MURRAY, K.J., BROWN, A.M., SANDERS, L. & BROWN, M.J. (1989). A receptor for 5-HT in human atrium. Br. J. Pharmacol., 98, 664 P.
  • KAUMANN, A.J. & SANDERS, L. (1994). 5-Hydroxytryptamine causes rate-dependent arrhythmias through 5-HT4 receptors in human atrium: facilitation by chronic β-adrenoceptor blockade. Naunyn-Schmiedeberg's Arch. Pharmacol., 349, 331–337.
  • KAUMANN, A.J. & SANDERS, L. (1998). 5-Hydroxytryptamine and human heart function: the role of 5-HT4 receptors. In 5-HT4 Receptors in the Brain and Periphery, ed. Eglen, R.M. pp. 127–148. Georgetown, Tex: RG Landes.
  • KAUMANN, A.J., SANDERS, L., BROWN, A.M., MURRAY, K.J. & BROWN, M.J. (1990). A 5-hydroxytryptamine receptor in human atrium. Br. J. Pharmacol., 100, 879–885.
  • KAUMANN, A.J., SANDERS, L., BROWN, A.M., MURRAY, K.J. & BROWN, M.J. (1991). A 5-HT4-like receptor in human right atrium. Naunyn-Schmiedeberg's Arch. Pharmacol., 344, 150–159.
  • KENAKIN, T. (1995). Agonist-receptor efficacy. I: Mechanisms of efficacy and receptor promiscuity. Trends Pharmacol. Sci., 16, 188–192.
  • KENAKIN, T.P. & MORGAN, P.H. (1989). Theoretical effects of single and multiple transducer receptor coupling proteins on estimates of the relative potency of agonists. Mol. Pharmacol., 35, 214–222.
  • KILTS, J.D., AKAZAWA, T., EL MOALEM, H.E., MATHEW, J.P., NEWMAN, M.F. & KWATRA, M.M. (2003). Age increases expression and receptor-mediated activation of Gi in human atria. J. Cardiovasc. Pharmacol., 42, 662–670.
  • LANGLOIS, M. & FISCHMEISTER, R. (2003). 5-HT4 receptor ligands: applications and new prospects. J. Med. Chem., 46, 319–344.
  • LORRAIN, J., GROSSET, A. & O'CONNOR, S.E. (1992). 5-HT4 receptors, present in piglet atria and sensitive to SDZ 205-557, are absent in papillary muscle. Eur. J. Pharmacol., 229, 105–108.
  • MARTIN, N.P., WHALEN, E.J., ZAMAH, M.A., PIERCE, K.L. & LEFKOWITZ, R.J. (2004). PKA-mediated phosphorylation of the β1-adrenergic receptor promotes Gs/Gi switching. Cell. Signal., 16, 1397–1403.
  • MATTIAZZI, A., GARAY, A. & CINGOLANI, H.E. (1986). Critical evaluation of isometric indexes of relaxation in rat and cat papillary muscles and toad ventricular strips. J. Mol. Cell. Cardiol., 18, 749–758.
  • MEDHURST, A.D. & KAUMANN, A.J. (1993). Characterization of the 5-HT4 receptor mediating tachycardia in piglet isolated right atrium. Br. J. Pharmacol., 110, 1023–1030.
  • MEDHURST, A.D., LEZOUALC'H, F., FISCHMEISTER, R., MIDDLEMISS, D.N. & SANGER, G.J. (2001). Quantitative mRNA analysis of five C-terminal splice variants of the human 5-HT4 receptor in the central nervous system by TaqMan real time RT–PCR. Brain Res. Mol. Brain Res., 90, 125–134.
  • MIALET, J., BERQUE-BESTEL, I., EFTEKHARI, P., GASTINEAU, M., GINER, M., DAHMOUNE, Y., DONZEAU-GOUGE, P., HOEBEKE, J., LANGLOIS, M., SICSIC, S., FISCHMEISTER, R. & LEZOUALC'H, F. (2000). Isolation of the serotoninergic 5-HT4(e) receptor from human heart and comparative analysis of its pharmacological profile in C6-glial and CHO cell lines. Br. J. Pharmacol., 129, 771–781.
    Direct Link:
  • MIALET, J., FISCHMEISTER, R. & LEZOUALC'H, F. (2003). Characterization of human 5-HT4(d) receptor desensitization in CHO cells. Br. J Pharmacol., 138, 445–452.
    Direct Link:
  • OUADID, H., SEGUIN, J., DUMUIS, A., BOCKAERT, J. & NARGEOT, J. (1992). Serotonin increases calcium current in human atrial myocytes via the newly described 5-hydroxytryptamine4 receptors. Mol. Pharmacol., 41, 346–351.
  • PARKER, S.G., TAYLOR, E.M., HAMBURGER, S.A., VIMAL, M. & KAUMANN, A.J. (1995). Blockade of human and porcine myocardial 5-HT4 receptors by SB 203186. Naunyn-Schmiedeberg's Arch. Pharmacol., 353, 28–35.
  • PAU, D., WORKMAN, A.J., KANE, K.A. & RANKIN, A.C. (2003). Electrophysiological effects of 5-hydroxytryptamine on isolated human atrial myocytes, and the influence of chronic β-adrenoceptor blockade. Br. J. Pharmacol., 140, 1434–1441.
    Direct Link:
  • PAU, D., WORKMAN, A., KANE, K. & RANKIN, A. (2005). Electrophysiological effects of prucalopride, a novel enterokinetic agent, on isolated atrial myocytes from patients treated with β-adrenoceptor antagonists. J. Pharmacol. Exp. Ther., 313, 146–153.
  • PERRY, S.J., BAILLIE, G.S., KOHOUT, T.A., MCPHEE, I., MAGIERA, M.M., ANG, K.L., MILLER, W.E., MCLEAN, A.J., CONTI, M., HOUSLAY, M.D. & LEFKOWITZ, R.J. (2002). Targeting of cyclic AMP degradation to β2-adrenergic receptors by β-arrestins. Science, 298, 834–836.
  • PINDON, A., VAN HECKE, G., VAN GOMPEL, P., LESAGE, A.S., LEYSEN, J.E. & JURZAK, M. (2002). Differences in signal transduction of two 5-HT4 receptor splice variants: compound specificity and dual coupling with Gs- and Gi/o-proteins. Mol. Pharmacol., 61, 85–96.
  • PINHEIRO, J.C. & BATES, D.M. (2000). Mixed Effects Models in S and S-plus, ed. Chambers, J., Eddy, W., Hardle, W., Sheather, S. & Tierney, L., New York: Springer-Verlag.
  • PINO, R., CERBAI, E., CALAMAI, G., ALAJMO, F., BORGIOLI, A., BRACONI, L., CASSAI, M., MONTESI, G.F. & MUGELLI, A. (1998). Effect of 5-HT4 receptor stimulation on the pacemaker currentIf in human isolated atrial myocytes. Cardiovasc. Res., 40, 516–522.
  • PONIMASKIN, E., DUMUIS, A., GAVEN, F., BARTHET, G., HEINE, M., GLEBOV, K., RICHTER, D.W. & OPPERMANN, M. (2005). Palmitoylation of the 5-hydroxytryptamine4(a) receptor regulates receptor phosphorylation, desensitization and β-Arrestin mediated endocytosis. Mol. Pharmacol., 67, 1434–1443.
  • QVIGSTAD, E., BRATTELID, T., SJAASTAD, I., ANDRESSEN, K.W., KROBERT, K.A., BIRKELAND, J.A., SEJERSTED, O.M., KAUMANN, A.J., SKOMEDAL, T., OSNES, J.B. & LEVY, F.O. (2005). Appearance of a ventricular 5-HT4 receptor-mediated inotropic response to serotonin in heart failure. Cardiovasc. Res., 65, 869–878.
  • RAHME, M.M., COTTER, B., LEISTAD, E., WADHWA, M.K., MOHABIR, R., FORD, A.P., EGLEN, R.M. & FELD, G.K. (1999). Electrophysiological and antiarrhythmic effects of the atrial selective 5-HT4 receptor antagonist RS-100302 in experimental atrial flutter and fibrillation. Circulation, 100, 2010–2017.
  • RAYMOND, J.R., MUKHIN, Y.V., GELASCO, A., TURNER, J., COLLINSWORTH, G., GETTYS, T.W., GREWAL, J.S. & GARNOVSKAYA, M.N. (2001). Multiplicity of mechanisms of serotonin receptor signal transduction. Pharmacol. Ther., 92, 179–212.
  • ROCHAIS, F., VANDECASTEELE, G., LEFEBVRE, F., LUGNIER, C., LUM, H., MAZET, J.L., COOPER, D.M. & FISCHMEISTER, R. (2004). Negative feedback exerted by cAMP-dependent protein kinase and cAMP phosphodiesterase on subsarcolemmal cAMP signals in intact cardiac myocytes: an in vivo study using adenovirus-mediated expression of CNG channels. J. Biol. Chem., 279, 52095–52105.
  • RONDE, P., ANSANAY, H., DUMUIS, A., MILLER, R. & BOCKAERT, J. (1995). Homologous desensitization of 5-hydroxytryptamine4 receptors in rat esophagus: functional and second messenger studies. J. Pharmacol. Exp. Ther., 272, 977–983.
  • SANDERS, L. & KAUMANN, A.J. (1992). A 5-HT4-like receptor in human left atrium. Naunyn-Schmiedeberg's Arch. Pharmacol., 345, 382–386.
  • SANDERS, L., LYNHAM, J.A., BOND, B., DEL MONTE, F., HARDING, S.E. & KAUMANN, A.J. (1995). Sensitization of human atrial 5-HT4 receptors by chronic β-blocker treatment. Circulation, 92, 2526–2539.
  • SAUDOU, F. & HEN, R. (1994). 5-Hydroxytryptamine receptor subtypes: molecular and functional diversity. Adv. Pharmacol., 30, 327–380.
  • SAXENA, P.R. (1995). Serotonin receptors: subtypes, functional responses and therapeutic relevance. Pharmacol. Ther., 66, 339–368.
  • SCHOEMAKER, R.G., DU, X.Y., BAX, W.A., BOS, E. & SAXENA, P.R. (1993). 5-Hydroxytryptamine stimulates human isolated atrium but not ventricle. Eur. J. Pharmacol., 230, 103–105.
  • SCHOEMAKER, R.G., DU, X.Y., BAX, W.A. & SAXENA, P.R. (1992). 5-Hydroxytryptamine increases contractile force in porcine right atrium but not in left ventricle. Naunyn-Schmiedeberg's Arch. Pharmacol., 346, 486–489.
  • ULENS, C. & TYTGAT, J. (2001). Gi- and Gs-coupled receptors up-regulate the cAMP cascade to modulate HCN2, but not HCN1 pacemaker channels. PflugersArch., 442, 928–942.
  • VERBEKE, G. & MOLENBERGHS, G. (2005). Linear Mixed Models in Practice. A SAS-Oriented Approach. Berlin: Springer-Verlag.
  • VILARO, M.T., DOMENECH, T., PALACIOS, J.M. & MENGOD, G. (2002). Cloning and characterization of a novel human 5-HT4 receptor variant that lacks the alternatively spliced carboxy terminal exon. RT–PCR distribution in human brain and periphery of multiple 5-HT4 receptor variants. Neuropharmacology, 42, 60–73.
  • VILLALON, C.M., DEN BOER, M.O., HEILIGERS, J.P. & SAXENA, P.R. (1991). Further characterization, by use of tryptamine and benzamide derivatives, of the putative 5-HT4 receptor mediating tachycardia in the pig. Br. J. Pharmacol., 102, 107–112.
  • VONESH, E.F. & CHINCHILLI, V.M. (1997). Linear and Nonlinear Models for the Analysis of Repeated Measurements. New York: Marcel-Dekker.
  • WORKMAN, A.J. & RANKIN, A.C. (1998). Serotonin, If and human atrial arrhythmia. Cardiovasc. Res., 40, 436–437.
  • XIANG, Y. & KOBILKA, B. (2003). The PDZ-binding motif of the β2-adrenoceptor is essential for physiologic signaling and trafficking in cardiac myocytes. Proc. Natl. Acad. Sci. U.S.A., 100, 10776–10781.
  • ZACCOLO, M. & POZZAN, T. (2002). Discrete microdomains with high concentration of cAMP in stimulated rat neonatal cardiac myocytes. Science, 295, 1711–1715.
View Full Article (HTML) Get PDF (323K)